United States: Bill To Undo Mensing Decision And Allow Patients To Sue Generic Drug Makers For Failure To Warn

Senator Patrick Leahy (D-Vt.) introduced legislation yesterday to counter the effect of the Supreme Court's June 2011 decision in Pliva v. Mensing, 131 S. Ct. 2567 (2011). Mensing held that patients who claim injury from generic drugs cannot sue the manufacturer for failure to warn, even though patients who take the same drug, but the brand name, can. Senator Leahy's bill is intended to undo this perceived inequality. If it succeeds, the bill would not only place a heavy burden on generic manufacturers contrary to the intent of the Hatch-Waxman Act, but it would also ignore the reality of how prescription drugs are used in the healthcare system.

WYETH V. LEVINE: BRAND NAME MANUFACTURERS CAN BE LIABLE

In 2009, the Supreme Court decided the landmark case of Wyeth v. Levine, 555 US 555 (2009). Diana Levine, a guitarist, was given the drug Phenergan, developed gangrene, and had to have her arm amputated. She sued Wyeth, the manufacturer of the drug, claiming that its warning was inadequate.

Wyeth argued that Levine's claims were preempted because FDA approval of the warning in question immunized Wyeth from liability. The Supreme Court disagreed, finding that Wyeth could have strengthened its warning without prior FDA approval using the "Changes Being Effected" ("CBE") supplement. Central to the Court's decision was the notion that a drug manufacturer must maintain responsibility for the content of its labels.

MURKY WATERS: LEVINE MEETS HATCH-WAXMAN

The Supreme Court made clear that its ruling in Levine applied only to brand name drugs. The ruling left open the question of whether generic manufacturers could be held liable in similar fashion in light of certain restrictions placed on generics by the Hatch-Waxman Amendments of 1984 ("Hatch-Waxman").

Hatch-Waxman was intended to bring generic drugs to the market quickly and inexpensively. In exchange for this expedited approval process, generic drug manufacturers were required to ensure that their products were identical to the Reference Listed Drug ("RLD"), or brand name drug, in certain respects. In particular, Hatch-Waxman required that generics maintain labeling identical to that of the RLD.

Courts and litigants alike had already been divided on the relationship between the CBE and sameness requirements. Some courts read the sameness requirement to prohibit generic manufacturers from submitting CBEs. Other courts stuck to traditional notions of manufacturer responsibility, holding that generics were held to the Levine standard and, therefore, could use CBEs to strengthen warnings. The latter position necessarily allowed a generic label to deviate from the RLD, despite statutory language to the contrary. The case law provided no conflicting guidance to the generic pharmaceutical industry.

SUPREME COURT REJECTS "SIMILAR PRE-EMPTION ACROSS A DISSIMILAR STATUTORY SCHEME"

In 2011, the Mensing decision resolved this tension. Citing Hatch-Waxman and regulations enacted by FDA, the Supreme Court held that generic manufacturers' labels could not deviate from the RLD label, and therefore could not be held liable for failure to warn.

Yet the core of this solution presented an inherent "inequality." The Mensing decision delineated two categories of plaintiffs: those who took brand name drugs, and those who took generics. Despite Hatch-Waxman's emphasis on "sameness," brand name drugs now carried the right to sue, while generics did not. Although the Court recognized this unfairness it refused to "distort the Supremacy Clause in order to create similar pre-emption across a dissimilar statutory scheme." Instead, the policy question was left to Congress and the FDA.

LEAHY'S BILL ALLOWS GENERIC LABELS TO DEVIATE

In response to several consumer advocacy groups, yesterday on the Senate floor Senator Leahy introduced S. 2295, 112th Cong. (2d. Sess. 2012) titled "Patient Safety and Generic Labeling Improvement Act." Senators Al Franken (D-Minn.), Jeff Bingaman (D-N.M.), Sherrod Brown (D-Ohio), Sheldon Whitehouse (D-R.I.), Chris Coons (D-Del.), and Richard Blumenthal (D-Conn.) co-sponsored the bill. A parallel bill was introduced in the House by Congressmen Chris Van Hollen (D-Md.) and Bruce Braley (D-Iowa).

The bill would permit generic drug manufacturers to change their labels "in the same manner" as brand name drug manufacturers. In essence, the proposed legislation permits generic manufacturers to submit CBE labeling changes. In addition, the bill would allow the FDA to order all other generics and the RLD holder to conform to the changes made by the generic drug manufacturer.

Senator Leahy noted that the legislation was introduced to directly address the perceived inequality created by the Supreme Court's decision. He cited an editorial published by The New York Times in March, as well as letters of support from the AARP, Alliance of Justice, and Public Citizen. He concluded that the legislation "will promote accountability and ensure that all drug makers can take appropriate steps to enhance warnings given to doctors and consumers."

DOING AWAY WITH "SAMENESS" COMPLICATES THE SYSTEM

What Senator Leahy failed to address, however, is the chaos and disarray that would result from the proposed amendment, and the realities of modern healthcare. Under this amendment, it is feasible that multiple labels for the same drug, each containing a different set of warnings. Healthcare practitioners and patients are already over-saturated with warnings. If a physician reads one label, he or she is unlikely to read any additional labels. Accordingly, the proposed legislation would only increase confusion without any demonstrated potential to increase patient safety.

Empowering, but not obligating, the FDA to order conformity does little to mitigate this problem. The nature of regulatory approval is that it can take months for the FDA to evaluate and approve modified warnings. Currently, CBE warning changes are implemented unilaterally by the RLD holder; only after the FDA approves the CBE submission are generics then permitted to change their labels accordingly. Under this new system there could be long periods of time where multiple warnings and labels are on the market.

LEGISLATIVE AMENDMENTS SHOULD TRY TO PRESERVE SAMENESS

Ultimately, given the Republican majority in the House of Representatives, this legislation is unlikely to pass both the House and the Senate in its current form. However, it is equally unlikely to be the last word from the legislature in response to the Supreme Court's suggestion that legislative change could address the inequality created by Mensing. Other alternatives may surface, such as obligating generics to inform FDA if they believe a label change is called for, but leaving it to FDA to use that information to mandate a uniform label across all versions of a drug, generic or branded.

Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Morrison & Foerster LLP. All rights reserved

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Erin M. Bosman
Julie Y. Park
 
In association with
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement

    Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of www.mondaq.com

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

    Disclaimer

    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

    Registration

    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

    Cookies

    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

    Links

    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

    Mail-A-Friend

    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

    Emails

    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

    Security

    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at enquiries@mondaq.com.

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions